Cost Burdens on Patients Older than 66 with Oral Cavity, Pharyngeal Cancers
the Cancer Therapy Advisor take:
Several factors including demographics, comorbidities, and treatment selection are associated with the burdensome Medicare cost of oral and pharyngeal cancer in older patients, according to an article published online in the journal JAMA Otolaryngology—Head & Neck Surgery.
Participants in this study included patients 66 and older with newly diagnosed oral cavity (n = 6,724) and pharyngeal (n = 3,987) cancers between January 1, 1995, and December 31, 2005.
Results showed demographics, comorbidities, and treatment types were all associated with a significant cost increase. African Americans accumulated $11,450 (95% CI: $1,320, $22,299) more in costs for oral cavity cancer and $25,093 (95% CI: $14,917 - $ 34,985) more in costs for pharyngeal cancer.
The mean 5-year cumulative costs for patients with the presence of one or two comorbidities and oral cavity cancer increased by $13,342 (95% CI: $6248, $19,186) and $14,139 (95% CI: $6,009, $22,217) for those with pharyngeal cancer. With the presence of three or more comorbidities, the mean 5-year cumulative costs for patients with oral cavity cancer increased by $22,196 (95% CI: $15,319, $28,614), while an increase of $27,799 (95% CI: $19,139, $36,702) was observed for patients with pharyngeal cancer.
Patients with oral cavity and pharyngeal cancers who received chemotherapy accrued a mean of $26,919 (95% CI: $18,309, $35,056) and $37,407 (95% CI: $29,971, $44,644) more in Medicare costs by 5 years.
Several factors associated with the burdensome Medicare cost of oral and pharyngeal cancer in older patients.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
- Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer
- Cabozantinib Effective Regardless of PD-L1 Expression in RCC